Effect of Imeglimin on QT/QTc Intervals in Healthy Subjects

Phase 1 Completed 55 enrolled Poxel SA

RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to assess the effect of a single therapeutic dose and a single supra-therapeutic dose of imeglimin on the QT/QTc interval

Timeline

Start: 2016-09
Primary completion: 2016-12
Completion: 2016-12

Publications

Dubourg J, Perrimond-Dauchy S, Felices M, Bolze S, Voiriot P, Fouqueray P. Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus. Eur J Clin Pharmacol. 2020 Oct;76(10):1393-1400. doi: 10.1007/s00228-020-02929-6. Epub 2020 Jun 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Imeglimin	Small molecule	2250 mg	Oral
Subject	Imeglimin	Small molecule	6000 mg	Oral
Comparator	Moxifloxacin	Small molecule	400 mg	Oral

Effect of Imeglimin on QT/QTc Intervals in Healthy Subjects

Summary

Timeline

Publications

Drugs

Indications